Status:
COMPLETED
Post-Radioiodine Graves' Management: The PRAGMA-Study
Lead Sponsor:
Newcastle-upon-Tyne Hospitals NHS Trust
Collaborating Sponsors:
Cardiff and Vale University Health Board
Royal Devon and Exeter NHS Foundation Trust
Conditions:
Graves' Disease
Eligibility:
All Genders
18+ years
Brief Summary
Thyroid dysfunction following radioiodine for Graves' disease is common, potentially detrimental and avoidable. A variety of clinical strategies are employed in the post-radioiodine era util the patie...
Eligibility Criteria
Inclusion
- Out-patients 18 years of age or over, who have given written informed consent to participate in the study
- Diagnosed with Graves' disease
- Received radioiodine for treatment of Graves' disease
- Had a minimum of 12 months follow-up after RI
- Most recent RI dose 5 years ago or less at the time of enrollment
Exclusion
- Patients unable to give informed consent
- Age 17 years or younger
- Cause of thyrotoxicosis other than Graves' disease
- Patients who have had more than one dose of radioiodine can only be included in the study once, using data pertaining to their most recent treatment episode.
- Patients who might not adequately understand verbal explanations or written information given in English, or who have special communication needs
Key Trial Info
Start Date :
March 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
803 Patients enrolled
Trial Details
Trial ID
NCT01885533
Start Date
March 1 2013
End Date
December 1 2015
Last Update
March 30 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, England, United Kingdom, NE3 4HD
2
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom, NE1 4LP